[S3 guidelines on exocrine pancreatic cancer 2024 : Consequences for the surgical practice]

The updated S3 guidelines on exocrine pancreatic cancer (version 3.1, 2024) bring several practice-relevant adaptations for the diagnostics and treatment. The preoperative staging is extended and treatment decisions are influenced increasingly more by the tumor biology. Neoadjuvant treatment is the standard for borderline resectable and locally advanced pancreatic cancer with subsequent surgical resection as the treatment target. Primary resection remains the standard for clearly resectable pancreatic cancer. A secondary resection is possible for selected M1 cases.